New approach for treating cystic fibrosis shows success in mice
Researchers have developed a potential strategy to treat cystic fibrosis, using oligonucleotides to correct certain gene defects.
List view / Grid view
Researchers have developed a potential strategy to treat cystic fibrosis, using oligonucleotides to correct certain gene defects.
In this ebook, discover how organoids can be used in regenerative medicine and how a novel AAV vector for gene therapy was developed.
Within this ebook, find articles on antibodies to combat SARS-CoV-2 and an evaluation of the various therapeutic forms they can take.
Two groups of infant rhesus macaques received one of two potential COVID-19 vaccines, which were shown to elicit high levels of neutralising antibodies.
Scientists have found differences in 206 genes between the GRCh38 (hg38) and GRCh37 (hg19) human reference genomes.
This issue includes articles on novel AAV vectors to deliver ocular gene therapy, how phenotypic models of disease are being used in covalent fragment screening and the challenges and opportunities presented by automation in the life sciences. Also in this issue are features on stem cells, antibodies and hit-to-lead.
Dr Björn Frendeus outlines how the growing biology surrounding the inhibitory Fc receptor FcγRIIb defines a target for improving existing and future antibody treatments.
For the first time, scientists have found evidence that polymerase theta can write RNA segments back into DNA.
Researchers have shown that omega-3 very long-chain polyunsaturated fatty acids can block SARS-CoV-2 and protect lung cells.
Researchers have created an algorithm that can predict the efficiencies of guide RNAs for CRISPR, potentially making it more precise.
Researchers have shown that the SARS-CoV-2 PLpro cuts human proteins so could potentially cause a range of COVID-19 symptoms.
Scientists have created new nanoparticle-based materials that could be used to deliver gene therapies in an adaptable way.
Despite the promise of gene therapies, significant challenges have emerged in the field. Dr Carsten Brunn discusses the current obstacles and opportunities when developing gene therapies.
Analysis of one million SARS-CoV-2 genome sequences has revealed a new variant named T478K, spreading mostly in Mexico.
Antibodies produced by B cells against the H1N1 influenza virus can also neutralise other strains, which could be used to developed vaccines.